Skip to main content
Caplight Logo









Philophos

Philophos

Private
DaejeonHealthcare & Life Scienceshttps://philophos.com

Last Round

Series A

Jan 24, 2022

Total Funding Raised

$1.51M

Company Overview

Philophos is a medical device company that develops and manufactures portable, low-cost optical coherence tomography (OCT) systems for medical diagnostics and tele-ophthalmology applications.

Sector

Healthcare & Life Sciences

Verticals

Medical Imaging, Medical Devices, Sensors, Health IoT

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Application

Keywords

optical coherence tomographyOCTportable medical devicespoint-of-care diagnosticstele-ophthalmologyhandheld OCTretinal imagingdermatological imagingmedical imaging hardwareOCT spectrometerindustrial inspectionOEM componentsremote diagnosticsmedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Philophos Comparables

Compare Philophos with similar companies based on industry and business-model similarity.

Philophos comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tishyas Medical Device Development Solutions
88%
Lumedica, Inc.
87%
Lumedica Vision
87%

Philophos Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 24, 2022
Pre SeedOct 17, 2019
AcceleratorMay 21, 2019

Key People

Founding team and executive leadership

Jung-Ho Chung

CEO & founder

Founding Team

Hyunho Oh

Chief Technology Officer

Executive Team

Philophos Investors

Notable investors and investment history

Philophos investors
InvestorRounds
Bluepoint PartnersPre Seed
Dadam InvestmentSeries A
ETRI HoldingsPre Seed
Industrial Bank of KoreaAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 24, 2022

    Raised $1.51M from Dadam Investment and kban-or.

  • Oct 17, 2019

    Raised Pre Seed round with Bluepoint Partners and ETRI Holdings.

Philophos Filings

Explore SEC and related filing metadata, where available.

Philophos filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Philophos's valuation, stock price, and market status.

Is Philophos a public or private company?

Philophos is a private company.

What is the current stock price of Philophos?

Philophos is a private company with no public stock price. No recent secondary market data is available.

How much is Philophos worth (valuation)?

Valuation information for Philophos is not publicly available.

Can I buy Philophos stock?

Philophos shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Philophos's last funding round?

Philophos's most recent funding round was Series A on January 24, 2022.

Who are the main investors in Philophos?

Key investors in Philophos include Bluepoint Partners, Dadam Investment, ETRI Holdings, Industrial Bank of Korea.

Will Philophos IPO soon?

No public IPO plans have been announced for Philophos.

How can I track Philophos secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Philophos's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDaejeon
Employee Range6
Year Founded2018
Last FundingJan 24, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?